RGBP (Regen BioPharma) Total Stockholders Equity: $-5.36 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regen BioPharma Total Stockholders Equity?

Regen BioPharma RGBP Total Stockholders Equity is $-5.36 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

Regen BioPharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-5.36 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Regen BioPharma's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Regen BioPharma's Debt-to-Equity for the quarter that ended in Mar. 2026 was -0.18.

Regen BioPharma  (OTCPK:RGBP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Regen BioPharma's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.359-0.015)/351.439
=-0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Regen BioPharma's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.959 + 0) / -5.359
=-0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Total Stockholders Equity Related Terms

Regen BioPharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Total Stockholders Equity Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.49 -8.04 -5.10 -5.22 -6.28

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.70 -5.82 -6.28 -6.57 -5.36
What does a Total Stockholders Equity of $-5.36 Mil mean?
Regen BioPharma (RGBP) has a Total Stockholders Equity of $-5.36 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Regen BioPharma and its competitors.
Is Regen BioPharma's Total Stockholders Equity too high?
Regen BioPharma's current Total Stockholders Equity is $-5.36 Mil.
How does Regen BioPharma's Total Stockholders Equity compare to SIGY and ENDV?
Regen BioPharma's Total Stockholders Equity of $-5.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Regen BioPharma and its competitors. Regen BioPharma's current Total Stockholders Equity is $-5.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.5% below its estimated fair value. The current Total Stockholders Equity is $-5.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Total Stockholders Equity is $-5.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.